Gilead announces results from Phase 2 Study showing reduction in atrial fibrillation burden with the investigational combination of ranolazine and low

12-05-2014 Business Wire HealthComments (0)

BiotechnologyGilead SciencesPharmaceuticalRanolazineUSA

Gilead Sciences (Nasdaq: GILD) today announced results from Harmony, a randomized, double-blind, placebo-controlled Phase 2 study evaluating the effect of ranolazine and low-dose dronedarone, each given alone and in combination, on atrial fibrillation burden (AFB) in patients with paroxysmal atrial fibrillation (AF). In Harmony, the combination of ranolazine and low-dose dronedarone provided greater reductions in AFB from baseline than either therapy used a

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top